Cargando…

Addition of (131)I-MIBG to PRRT ((90)Y-DOTATOC) for Personalized Treatment of Selected Patients with Neuroendocrine Tumors

Peptide receptor radionuclide therapy (PRRT) is an effective treatment for metastatic neuroendocrine tumors. Delivering a sufficient tumor radiation dose remains challenging because of critical-organ dose limitations. Adding (131)I-metaiodobenzylguanidine ((131)I-MIBG) to PRRT may be advantageous in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bushnell, David L., Bodeker, Kellie L., O’Dorisio, Thomas M., Madsen, Mark T., Menda, Yusuf, Graves, Stephen, Zamba, Gideon K.D., O’Dorisio, M. Sue
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Society of Nuclear Medicine 2021
Materias:	Theranostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8882893/ https://www.ncbi.nlm.nih.gov/pubmed/33517327 http://dx.doi.org/10.2967/jnumed.120.254987

Ejemplares similares

Feasibility and advantage of adding (131)I-MIBG to (90)Y-DOTATOC for treatment of patients with advanced stage neuroendocrine tumors
por: Bushnell, David L, et al.
Publicado: (2014)

Prospective Analysis of the Impact of (68)Ga-DOTATOC Positron Emission Tomography–Computerized Axial Tomography on Management of Pancreatic and Small Bowel Neuroendocrine Tumors
por: Ghobrial, Silvia N., et al.
Publicado: (2020)

Efficacy and Safety of High-Specific-Activity (131)I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma
por: Pryma, Daniel A., et al.
Publicado: (2019)

Gastroenteropancreatic neuroendocrine tumors in children and young adults
por: Khanna, Geetika, et al.
Publicado: (2007)

SUN-LB26 Radioligand Theranostics of Endocrine-Related Cancers; A New, Revolutionary Approach
por: Harris, Alan G, et al.
Publicado: (2020)

Opportunities to Improve Symptom Control with Somatostatin Congeners in GEP‐NETs: A Review of Key Issues
por: Anthony, Lowell B., et al.
Publicado: (2021)

Safety and Efficacy of Peptide-Receptor Radionuclide Therapy in Elderly Neuroendocrine Tumor Patients
por: Theiler, Deborah, et al.
Publicado: (2021)

Preclinical Characterization of the Radioimmunoconjugate (111)In or (90)Y-FF-21101 Against a P-Cadherin–Expressing Tumor in a Mouse Xenograft Model and a Nonhuman Primate
por: Funase, Yuichi, et al.
Publicado: (2021)

Growing vascular endothelial cells express somatostatin subtype 2 receptors
por: Watson, J C, et al.
Publicado: (2001)

Erratum to: The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours
por: Bodei, L., et al.
Publicado: (2013)

Head-to-Head Comparison of (68)Ga-Prostate-Specific Membrane Antigen PET/CT and Ferumoxtran-10–Enhanced MRI for the Diagnosis of Lymph Node Metastases in Prostate Cancer Patients
por: Schilham, Melline G.M., et al.
Publicado: (2021)

Imaging DNA Damage Repair In Vivo After (177)Lu-DOTATATE Therapy
por: O’Neill, Edward, et al.
Publicado: (2020)

(68)Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers
por: Giesel, Frederik L., et al.
Publicado: (2019)

Detection Efficacy of (18)F-PSMA-1007 PET/CT in 251 Patients with Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy
por: Giesel, Frederik L., et al.
Publicado: (2019)

Monosodium Glutamate Reduces (68)Ga-PSMA-11 Uptake in Salivary Glands and Kidneys in a Preclinical Prostate Cancer Model
por: Rousseau, Etienne, et al.
Publicado: (2018)

Synthesis and Preclinical Characterization of the PSMA-Targeted Hybrid Tracer PSMA-I&F for Nuclear and Fluorescence Imaging of Prostate Cancer
por: Schottelius, Margret, et al.
Publicado: (2019)

Radiohybrid Ligands: A Novel Tracer Concept Exemplified by (18)F- or (68)Ga-Labeled rhPSMA Inhibitors
por: Wurzer, Alexander, et al.
Publicado: (2020)

Synergistic Effect of a Mesothelin-Targeted (227)Th Conjugate in Combination with DNA Damage Response Inhibitors in Ovarian Cancer Xenograft Models
por: Wickstroem, Katrine, et al.
Publicado: (2019)

Enhancement of (211)At Uptake via the Sodium Iodide Symporter by the Addition of Ascorbic Acid in Targeted α-Therapy of Thyroid Cancer
por: Watabe, Tadashi, et al.
Publicado: (2019)

Development of Fibroblast Activation Protein–Targeted Radiotracers with Improved Tumor Retention
por: Loktev, Anastasia, et al.
Publicado: (2019)

Bone Marrow Absorbed Doses and Correlations with Hematologic Response During (177)Lu-DOTATATE Treatments Are Influenced by Image-Based Dosimetry Method and Presence of Skeletal Metastases
por: Hagmarker, Linn, et al.
Publicado: (2019)

A Prospective Study on (18)F-DCFPyL PSMA PET/CT Imaging in Biochemical Recurrence of Prostate Cancer
por: Rousseau, Etienne, et al.
Publicado: (2019)

FAPI-74 PET/CT Using Either (18)F-AlF or Cold-Kit (68)Ga Labeling: Biodistribution, Radiation Dosimetry, and Tumor Delineation in Lung Cancer Patients
por: Giesel, Frederik L., et al.
Publicado: (2021)

Diagnostic Accuracy of (18)F-PSMA-1007 PET/CT Imaging for Lymph Node Staging of Prostate Carcinoma in Primary and Biochemical Recurrence
por: Sprute, Katharina, et al.
Publicado: (2021)

The current status of somatostatin receptors in malignant melanoma.
por: Fletcher, W. S., et al.
Publicado: (1997)

VPAC1 receptor (Vipr1)-deficient mice exhibit ameliorated experimental autoimmune encephalomyelitis, with specific deficits in the effector stage
por: Abad, Catalina, et al.
Publicado: (2016)

Erratum to: VPAC1 receptor (Vipr1)-deficient mice exhibit ameliorated experimental autoimmune encephalomyelitis, with specific deficits in the effector stage
por: Abad, Catalina, et al.
Publicado: (2017)

Management of Diarrhea in Patients With Carcinoid Syndrome
por: Naraev, Boris G., et al.
Publicado: (2019)

Auranofin Inhibition of Thioredoxin Reductase in a Preclinical Model of Small Cell Lung Cancer
por: Johnson, Spenser S., et al.
Publicado: (2023)

[(68)Ga]DOTATOC PET/CT Radiomics to Predict the Response in GEP-NETs Undergoing [(177)Lu]DOTATOC PRRT: The “Theragnomics” Concept
por: Laudicella, Riccardo, et al.
Publicado: (2022)

The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours
por: Zaknun, John J., et al.
Publicado: (2013)

Establishment of Novel Neuroendocrine Carcinoma Patient-Derived Xenograft Models for Receptor Peptide-Targeted Therapy
por: Tran, Catherine G., et al.
Publicado: (2022)

Iodine-131MIBG SPECT/CT in neuroendocrine tumours: An institutional experience
por: Verma, Priyanka, et al.
Publicado: (2012)

Clinical, Diagnostic, and Treatment Characteristics of SDHA-Related Metastatic Pheochromocytoma and Paraganglioma
por: Jha, Abhishek, et al.
Publicado: (2019)

Patient-reported Symptom Experiences in Patients With Carcinoid Syndrome After Participation in a Study of Telotristat Etiprate: A Qualitative Interview Approach
por: Gelhorn, Heather L., et al.
Publicado: (2016)

Relevance of Volumetric Parameters Applied to [(68)Ga]Ga-DOTATOC PET/CT in NET Patients Treated with PRRT
por: Urso, Luca, et al.
Publicado: (2023)

The use of 131I-MIBG in the imaging of metastatic carcinoid tumours.
por: Jodrell, D. I., et al.
Publicado: (1988)

Sequelae and survivorship in patients treated with (131)I-MIBG therapy
por: Sze, W C C, et al.
Publicado: (2013)

Predictive and Prognostic Role of Pre-Therapy and Interim 68Ga-DOTATOC PET/CT Parameters in Metastatic Advanced Neuroendocrine Tumor Patients Treated with PRRT
por: Durmo, Rexhep, et al.
Publicado: (2022)

(131)I-metaiodobenzylguanidine ((131)I-MIBG) therapy for residual neuroblastoma: a mono-institutional experience with 43 patients
por: Garaventa, A, et al.
Publicado: (1999)

Cannot write session to /tmp/vufind_sessions/sess_gcgisoqno0rum9dnuagvo2asb1